CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced findings from the SHORE (Surveillance HeartCare Outcomes Registry) study, one of the largest heart transplant studies of its kind, published in The Journal of Heart and Lung Transplantation.

On December 14, Beijing Hotgen Biotech Co., Ltd. announced that the company intends to acquire 38.0993% equity interest in Oriomics by way of equity transfer and subscription of additional registered capital at a price of CNY 153 million.